SG11201911919PA - Image capillary isoelectric focusing to analyze protein variants in a sample matrix - Google Patents
Image capillary isoelectric focusing to analyze protein variants in a sample matrixInfo
- Publication number
- SG11201911919PA SG11201911919PA SG11201911919PA SG11201911919PA SG11201911919PA SG 11201911919P A SG11201911919P A SG 11201911919PA SG 11201911919P A SG11201911919P A SG 11201911919PA SG 11201911919P A SG11201911919P A SG 11201911919PA SG 11201911919P A SG11201911919P A SG 11201911919PA
- Authority
- SG
- Singapore
- Prior art keywords
- tarrytown
- regeneron
- saw mill
- international
- old saw
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 238000000533 capillary isoelectric focusing Methods 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 abstract 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 108010081667 aflibercept Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/24—Extraction; Separation; Purification by electrochemical means
- C07K1/26—Electrophoresis
- C07K1/28—Isoelectric focusing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44795—Isoelectric focusing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/60—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrostatic variables, e.g. electrographic flaw testing
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547602P | 2017-08-18 | 2017-08-18 | |
| PCT/US2018/046893 WO2019036604A1 (en) | 2017-08-18 | 2018-08-17 | IMAGE CAPILLARY ISOELECTRIC FOCUSING FOR ANALYSIS OF PROTEIN VARIANTS IN A SAMPLING MATRIX |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911919PA true SG11201911919PA (en) | 2020-02-27 |
Family
ID=65361327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911919PA SG11201911919PA (en) | 2017-08-18 | 2018-08-17 | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190056350A1 (es) |
| EP (1) | EP3668546A4 (es) |
| JP (2) | JP7399845B2 (es) |
| KR (2) | KR102584848B1 (es) |
| CN (1) | CN111132695A (es) |
| AR (1) | AR112783A1 (es) |
| AU (1) | AU2018317438A1 (es) |
| CA (1) | CA3065562A1 (es) |
| EA (1) | EA202090515A1 (es) |
| IL (2) | IL271237B2 (es) |
| MX (2) | MX2020001818A (es) |
| SG (1) | SG11201911919PA (es) |
| TW (2) | TWI844883B (es) |
| WO (1) | WO2019036604A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018317438A1 (en) * | 2017-08-18 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
| WO2021072230A1 (en) * | 2019-10-10 | 2021-04-15 | Regeneron Pharmaceuticals, Inc. | Liquid chromatography-mass spectrometry (lc-ms) methods for analyzing ampholyte lot variation |
| WO2023177836A1 (en) * | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| KR100958165B1 (ko) * | 2008-05-26 | 2010-05-14 | 연세대학교 산학협력단 | 비젤방식의 2차원 단백질분리용 다중채널장치 |
| FR2947632B1 (fr) * | 2009-07-01 | 2011-11-11 | Sebia Sa | Analyse et dosage d'hemoglobines glyquees par electrophorese capillaire, compositions tampon et kits pour electrophorese capillaire |
| EP2758073B1 (en) | 2011-09-23 | 2018-10-31 | OncoMed Pharmaceuticals, Inc. | Vegf/dll4 binding agents and uses thereof |
| AU2013256229A1 (en) * | 2012-05-03 | 2014-10-30 | Medimmune, Llc | Method for analyzing sample components |
| UY36370A (es) * | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Polipéptidos fgf-21 modificados y sus usos |
| WO2016070062A2 (en) * | 2014-10-31 | 2016-05-06 | Genentech, Inc. | Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MY188749A (en) | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| JP6882738B2 (ja) * | 2015-11-18 | 2021-06-02 | フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ | Ｖｅｇｆ阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ |
| ES2981791T3 (es) * | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| AU2018317438A1 (en) * | 2017-08-18 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
-
2018
- 2018-08-17 AU AU2018317438A patent/AU2018317438A1/en active Pending
- 2018-08-17 SG SG11201911919PA patent/SG11201911919PA/en unknown
- 2018-08-17 IL IL271237A patent/IL271237B2/en unknown
- 2018-08-17 MX MX2020001818A patent/MX2020001818A/es unknown
- 2018-08-17 TW TW111126023A patent/TWI844883B/zh active
- 2018-08-17 AR ARP180102365A patent/AR112783A1/es unknown
- 2018-08-17 KR KR1020207000244A patent/KR102584848B1/ko active IP Right Grant
- 2018-08-17 EP EP18845630.5A patent/EP3668546A4/en active Pending
- 2018-08-17 CN CN201880053645.8A patent/CN111132695A/zh active Pending
- 2018-08-17 JP JP2020502363A patent/JP7399845B2/ja active Active
- 2018-08-17 US US16/104,355 patent/US20190056350A1/en not_active Abandoned
- 2018-08-17 EA EA202090515A patent/EA202090515A1/ru unknown
- 2018-08-17 IL IL312394A patent/IL312394A/en unknown
- 2018-08-17 CA CA3065562A patent/CA3065562A1/en active Pending
- 2018-08-17 WO PCT/US2018/046893 patent/WO2019036604A1/en unknown
- 2018-08-17 TW TW107128788A patent/TWI774827B/zh active
- 2018-08-17 KR KR1020237033115A patent/KR20230141948A/ko not_active Application Discontinuation
-
2020
- 2020-02-14 MX MX2024004106A patent/MX2024004106A/es unknown
-
2022
- 2022-06-10 US US17/837,550 patent/US20220317088A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112421A patent/JP2023145494A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019036604A9 (en) | 2019-04-04 |
| EP3668546A1 (en) | 2020-06-24 |
| IL271237B2 (en) | 2024-10-01 |
| US20220317088A1 (en) | 2022-10-06 |
| CA3065562A1 (en) | 2019-02-21 |
| CN111132695A (zh) | 2020-05-08 |
| WO2019036604A1 (en) | 2019-02-21 |
| IL271237A (en) | 2020-01-30 |
| IL271237B1 (en) | 2024-06-01 |
| JP7399845B2 (ja) | 2023-12-18 |
| MX2024004106A (es) | 2024-04-25 |
| TWI844883B (zh) | 2024-06-11 |
| AR112783A1 (es) | 2019-12-11 |
| KR20200078466A (ko) | 2020-07-01 |
| KR20230141948A (ko) | 2023-10-10 |
| EA202090515A1 (ru) | 2020-05-26 |
| TW202242403A (zh) | 2022-11-01 |
| MX2020001818A (es) | 2020-07-13 |
| KR102584848B1 (ko) | 2023-10-04 |
| TWI774827B (zh) | 2022-08-21 |
| IL312394A (en) | 2024-06-01 |
| US20190056350A1 (en) | 2019-02-21 |
| JP2023145494A (ja) | 2023-10-11 |
| JP2020531802A (ja) | 2020-11-05 |
| TW201920927A (zh) | 2019-06-01 |
| EP3668546A4 (en) | 2021-05-12 |
| AU2018317438A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901180WA (en) | Systems and methods for providing identity assurance for decentralized applications | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
| SG11201811405QA (en) | Improved differentiation method | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201806781SA (en) | Registry and automated management method for blockchain-enforced smart contracts | |
| SG11201809649WA (en) | Macromolecule analysis employing nucleic acid encoding | |
| SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
| SG11201907770YA (en) | Systems and methods for determining a parking region of vehicles | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201805906WA (en) | Diagnostic and prognostic methods for cardiovascular diseases and events | |
| SG11201903302UA (en) | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201806404SA (en) | Systems and methods for storing and sharing transactional data using distributed computer systems | |
| SG11202000330XA (en) | Concept for generating an enhanced sound field description or a modified sound field description using a multi-point sound field description | |
| SG11201803666WA (en) | Single image detection | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201805255TA (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |